Intorio, Corp. SEC 10-Q Report

Intorio, Corp., now operating as REDOX International Group, has released its Form 10-Q report for the third quarter ending November 30, 2024. The report provides a detailed overview of the company's financial performance and operational activities, highlighting significant changes and future plans in the functional medicine and health management services industry.

Financial Highlights

• Revenues: $0. The company did not generate any revenue during the three months ended November 30, 2024, compared to $2,000 in the same period in 2023.
• Gross Profit from Operations: $0. No gross profit was recorded for the three months ended November 30, 2024, due to the absence of revenue.
• Income (loss) from operations before provision for income tax benefit (expense): $(14,293). The company reported an operating loss for the three months ended November 30, 2024, primarily due to professional fees and other operating expenses.
• Net Income (loss): $(14,293). The net loss for the three months ended November 30, 2024, was significantly higher than the loss of $(2,425) in the same period in 2023.
• Net Income (loss) per share: Basic and diluted: $0. The company reported no earnings per share for the three months ended November 30, 2024, as there was no net income.

Business Highlights

• Business Overview: Intorio, Corp., now doing business as REDOX International Group, focuses on functional medicine and health management services. The company operates a comprehensive functional medicine laboratory and a teaching clinic in Asia, aiming to improve health management and disease prevention.
• Recent Developments: On May 16, 2024, the company underwent a significant ownership change, with Dr. Han-Wen Ou appointed as the new CEO. The company is also in the process of changing its name to REDOX International Group and has registered its DBA with the state of Nevada and California.
• Operational Focus: REDOX is dedicated to promoting functional medicine through its laboratory and clinical services, offering a range of health management services including clinical consultation, nutrition advisory, and medical assessments.
• Future Outlook: The company plans to continue expanding its functional medicine services and aims to improve the domestic health management environment through diversified market services. It anticipates the need for additional capital to support its operations and growth plans.
• Management's Discussion: The company acknowledges the need for additional capital to meet long-term operating requirements and plans to raise funds through equity or debt securities. It also highlights the importance of functional medicine in its business strategy and aims to enhance its market presence in Asia.

SEC Filing: Intorio, Corp. [ ITOR ] - 10-Q - Feb. 19, 2025